Journal of Internal Medicine Concepts & Practice >

2025 , Vol. 20 >Issue 05: 405 - 409

DOI: https://doi.org/10.16138/j.1673-6087.2025.05.11

Advances in the study of intestinal microbes and rheumatic immune diseases

  • LIU Qilong ,
  • JIN Zhengyi ,
  • HU Jiaqi ,
  • MIN Dumu ,
  • MA Taiyan ,
  • GAO Jie
Expand
  • Department of Rheumatology and Immunology, the First Affiliated Hospital of Naval Medical University, Shanghai 200433, China

Received date: 2024-11-07

  Online published: 2025-12-26

Copyright

, 2025, Copyright reserved © 2025.
Fold

Abstract

The gut microbes are crucial for maintaining human health. Intestinal microorganisms and their metabolites participate in the occurrence and development of rheumatic immune diseases by regulating inflammatory factors and immune cells. More studies show that intestinal microbial imbalance is closely related to the pathogenesis of rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis and other rheumatic immune diseases. Recently, transplantation of probiotics and fecal microbiota as emerging therapeutic approaches has shown preliminary efficacy. With the rapid development of metagenomics, in-depth study on gut microbes will provide new perspective and potential intervention strategies for the diagnosis, treatment and prevention of rheumatic immune diseases. This article reviews the role and potential therapeutic effects of gut microbes in rheumatic immune diseases.

Key words： Gut microbiota; Autoimmune rheumatic diseases; Probiotics; Fecal microbiota transplantation

Cite this article

LIU Qilong , JIN Zhengyi , HU Jiaqi , MIN Dumu , MA Taiyan , GAO Jie . Advances in the study of intestinal microbes and rheumatic immune diseases[J]. Journal of Internal Medicine Concepts & Practice, 2025 , 20(05) : 405 -409 . DOI: 10.16138/j.1673-6087.2025.05.11

References

[1] Lu ZF, Hsu CY, Younis NK, et al. Exploring the significance of microbiota metabolites in rheumatoid arthritis: uncovering their contribution from disease development to biomarker potential[J]. APMIS, 2024, 132(6): 382-415.
[2] Lian FP, Zhang F, Zhao CM, et al. Gut microbiota regulation of T lymphocyte subsets during systemic lupus erythematosus[J]. BMC Immunol, 2024, 25(1): 41.
[3] Kalayci FNC, Ozen S. Possible role of dysbiosis of the gut microbiome in SLE[J]. Curr Rheumatol Rep, 2023, 25(12): 247-258.
[4] Zhao Y, Cheng M, Zou L, et al. Hidden link in gut-joint axis: gut microbes promote rheumatoid arthritis at early stage by enhancing ascorbate degradation[J]. Gut, 2022, 71(5): 1041-1043.
[5] Bao Y, Dong C, Ji J, et al. Dysregulation of gut microbiome is linked to disease activity of rheumatic diseases[J]. Clin Rheumatol, 2020, 39(9): 2523-2528.
[6] Krautkramer KA, Fan J, B?ckhed F. Gut microbial metabolites as multi-kingdom intermediates[J]. Nat Rev Microbiol, 2021, 19(2): 77-94.
[7] Dubik M, Pilecki B, Moeller JB. Commensal intestinal protozoa-underestimated members of the gut microbial community[J]. Biology (Basel), 2022, 11(12): 1742.
[8] Wu G, Xu T, Zhao N, et al. A core microbiome signature as an indicator of health [J]. Cell, 2024, 187(23): 6550-6565.
[9] Bi Y, Tu Y, Zhang N, et al. Multiomics analysis reveals the presence of a microbiome in the gut of fetal lambs[J]. Gut, 2021, 70(5): 853-864.
[10] Enriquez AB, Ten Caten F, Ghneim K, et al. Regulation of immune homeostasis, inflammation, and HIV persistence by the microbiome, short-chain fatty acids, and bile acids[J]. Annu Rev Virol, 2023, 10(1): 397-422.
[11] Yang W, Cong Y. Gut microbiota-derived metabolites in the regulation of host immune responses and immune-related inflammatory diseases[J]. Cell Mol Immunol, 2021, 18(4): 866-877.
[12] Ghosh S, Whitley CS, Haribabu B, et al. Regulation of intestinal barrier function by microbial metabolites[J]. Cell Mol Gastroenterol Hepatol, 2021, 11(5): 1463-1482.
[13] Kayama H, Okumura R, Takeda K. Interaction between the microbiota, epithelia, and immune cells in the intestine[J]. Annu Rev Immunol, 2020, 38: 23-48.
[14] Zhao T, Wei Y, Zhu Y, et al. Gut microbiota and rheumatoid arthritis: from pathogenesis to novel therapeutic opportunities[J]. Front Immunol, 2022, 13: 1007165.
[15] Zhang L, Qing P, Yang H, et al. Gut microbiome and metabolites in systemic lupus erythematosus: link, mechanisms and intervention[J]. Front Immunol, 2021, 12: 686501.
[16] Huang T, Pu Y, Wang X, et al. Metabolomic analysis in spondyloarthritis: a systematic review[J]. Front Microbiol, 2022, 13: 965709.
[17] Wang Q, Zhang SX, Chang MJ, et al. Characteristics of the gut microbiome and its relationship with peripheral CD4+ T cell subpopulations and cytokines in rheumatoid arthritis[J]. Front Microbiol, 2022, 13: 799602.
[18] Drago L. Prevotella copri and microbiota in rheumatoid arthritis: fully convincing evidence?[J]. J Clin Med, 2019, 8(11): 1837.
[19] Guo R, Li S, Zhang Y, et al. Dysbiotic oral and gut viromes in untreated and treated rheumatoid arthritis patients[J]. Microbiol Spectr, 2022, 10(5): e0034822.
[20] Toumi E, Goutorbe B, Plauzolles A, et al. Gut microbiota in systemic lupus erythematosus patients and lupus mouse model: a cross species comparative analysis for biomarker discovery[J]. Front Immunol, 2022, 13: 943241.
[21] Chen C, Yan Q, Yao X, et al. Alterations of the gut virome in patients with systemic lupus erythematosus[J]. Front Immunol, 2023, 13: 1050895.
[22] Zhang L, Han R, Zhang X, et al. Fecal microbiota in patients with ankylosing spondylitis: correlation with dietary factors and disease activity[J]. Clin Chim Acta, 2019, 497: 189-196.
[23] Li C, Zhang Y, Yan Q, et al. Alterations in the gut virome in patients with ankylosing spondylitis[J]. Front Immunol, 2023, 14: 1154380.
[24] So J, Tam LS. Gut microbiome and its interaction with immune system in spondyloarthritis[J]. Microorganisms, 2020, 8(11): 1727.
[25] Wang X, Pang K, Wang J, et al. Microbiota dysbiosis in primary Sj?gren's syndrome and the ameliorative effect of hydroxychloroquine[J]. Cell Rep, 2022, 40(11): 111352.
[26] Tan TC, Chandrasekaran L, Leung YY, et al. Gut microbiome profiling in systemic sclerosis: a metagenomic approach[J]. Clin Exp Rheumatol, 2023, 41(8): 1578-1588.
[27] Yang Y, Hong Q, Zhang X, et al. Rheumatoid arthritis and the intestinal microbiome: probiotics as a potential therapy[J]. Front Immunol, 2024, 15: 1331486.
[28] Balasundaram D, Veerasamy V, Sylvia Singarayar M, et al. Therapeutic potential of probiotics in gut microbial homeostasis and rheumatoid arthritis[J]. Int Immunopharmacol, 2024, 137: 112501.
[29] Bodkhe R, Balakrishnan B, Taneja V. The role of microbiome in rheumatoid arthritis treatment [J]. Ther Adv Musculoskelet Dis, 2019, 11:1759720X19844632.
[30] Ferro M, Charneca S, Dourado E, et al. Probiotic supplementation for rheumatoid arthritis: a promising adjuvant therapy in the gut microbiome era[J]. Front Pharmacol, 2021, 12: 711788.
[31] Fan Z, Yang B , Ross RP, et al. The prophylactic effects of different lactobacilli on collagen-induced arthritis in rats [J]. Food Funct, 2020, 11(4): 3681-3694.
[32] Zeng J, Peng L, Zheng W, et al. Fecal microbiota transplantation for rheumatoid arthritis: a case report[J]. Clin Case Rep, 2020, 9(2): 906-909.
[33] Huang C, Yi P, Zhu M, et al. Safety and efficacy of fecal microbiota transplantation for treatment of systemic lupus erythematosus: an EXPLORER trial[J]. J Autoimmun, 2022, 130: 102844.
[34] Wang L, Wei Z, Pan F, et al. Case report: fecal microbiota transplantation in refractory ankylosing spondylitis[J]. Front Immunol, 2023, 14: 1093233.
Options
Outlines

/

〈 〉